RU2014115476A - PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS - Google Patents
PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS Download PDFInfo
- Publication number
- RU2014115476A RU2014115476A RU2014115476/04A RU2014115476A RU2014115476A RU 2014115476 A RU2014115476 A RU 2014115476A RU 2014115476/04 A RU2014115476/04 A RU 2014115476/04A RU 2014115476 A RU2014115476 A RU 2014115476A RU 2014115476 A RU2014115476 A RU 2014115476A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- optionally substituted
- alkenyl
- same
- different
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1. Соединение формулы (I)или его фармацевтически приемлемая соль,где R представляет собой H или F;Zи Zнезависимо выбирают из группы, состоящей из CH и N;кольцо A представляет собой фенил, нафтил, ароматический 5-6-членный гетероциклил или ароматический 9-11-членный гетеробициклил, при этом кольцо A является необязательно замещенным одним или более R;каждый Rнезависимо представляет собой галоген, CN, C(O)OR, OR, C(O)R, C(O)N(RR), S(O)N(RR), S(O)N(RR), S(O)R, S(O)R, N(R)S(O)N(RR), N(R)S(O)N(RR), SR, N(RR), NO, OC(O)R, N(R)C(O)R, N(R)S(O)R, N(R)S(O)R, N(R)C(O)N(RR), N(R)C(O)OR, OC(O)N(RR), T, Cалкил, Cалкенил или Cалкинил, при этом Cалкил, Cалкенил и Cалкинил являются необязательно замещенными одним или более R, которые являются одинаковыми или различными;R, R, Rнезависимо выбирают из группы, состоящей из H, T, Cалкила, Cалкенила и Cалкинила, при этом Cалкил, Cалкенил и Cалкинил являются необязательно замещенными одним или более R, которые являются одинаковыми или различными;Rпредставляет собой галоген, CN, C(O)OR, OR, C(O)R, C(O)N(RR), S(O)N(RR), S(O)N(RR), S(O)R, S(O)R, N(R)S(O)N(RR), N(R)S(O)N(RR), SR, N(RR), NO, OC(O)R, N(R)C(O)R, N(R)S(O)R, N(R)S(O)R, N(R)C(O)N(RR), N(R)C(O)OR, OC(O)N(RR) или T;R, R, Rнезависимо выбирают из группы, состоящей из H, T, Cалкила, Cалкенила и Cалкинила, при этом Cалкил, Cалкенил и Cалкинил являются необязательно замещенными одним или более галогенами, которые являются одинаковыми или различными;Tпредставляет собой C-циклоалкил, насыщенный 4-7-членный гетероциклил или насыщенный 7-11-членный гетеробициклил, при этом Tявляется необязательно замещенным одним или более R, которые являются одинаковыми или различными;Y представляет собой CH;Xпредставляет собой C(R) или N;Xпредставляет собой C(R) или N;Xпредставляет собой C(R) или N;Xпредставляет собой C(R) или N;Xпредставляет собой C(R) или N, при условии, чт1. The compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is H or F; Z and Z are independently selected from the group consisting of CH and N; ring A is phenyl, naphthyl, aromatic 5-6 membered heterocyclyl, or aromatic 9-11 membered heterobicyclyl, wherein ring A is optionally substituted with one or more R; each R independently is halogen, CN, C (O) OR, OR, C (O) R, C (O) N (RR) S (O) N (RR), S (O) N (RR), S (O) R, S (O) R, N (R) S (O) N (RR), N (R) S (O ) N (RR), SR, N (RR), NO, OC (O) R, N (R) C (O) R, N (R) S (O) R, N (R) S (O) R , N (R) C (O) N (RR), N (R) C (O) OR, OC (O) N (RR), T, C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl, wherein C 1-6 alkyl, C 2 phenyl and C1-6alkynyl are optionally substituted with one or more R, which are the same or different; R, R, R are independently selected from the group consisting of H, T, C1-6alkyl, C1-6alkenyl and C1-6alkynyl, wherein more than R, which are the same or different; R is halogen, CN, C (O) OR, OR, C (O) R, C (O) N (RR), S (O) N (RR), S (O ) N (RR), S (O) R, S (O) R, N (R) S (O) N (RR), N (R) S (O) N (RR), SR, N (RR) , NO, OC (O) R, N (R) C (O) R, N (R) S (O) R, N (R) S (O) R, N (R) C (O) N (RR ), N (R) C (O) OR, OC (O) N (RR) or T; R, R, R are independently selected from the group consisting of H, T, C1-6 alkyl, C1-6 alkenyl and C1-4 nyl, wherein C1-6alkyl, C1-6alkenyl and C1-6alkynyl are optionally substituted with one or more halogens that are the same or different; T is C-cycloalkyl, saturated 4-7 membered heterocyclyl or saturated 7-11 membered heterobicyclic, wherein T is optionally substituted one or more R, which are the same or different; Y is CH; X is C (R) or N; X is C (R) or N; X is C (R) or N; X is C (R) or N; X is C (R) or N, provided that
Claims (23)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11182020.5 | 2011-09-20 | ||
EP11182020 | 2011-09-20 | ||
PCT/EP2012/068504 WO2013041605A1 (en) | 2011-09-20 | 2012-09-20 | Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014115476A true RU2014115476A (en) | 2015-10-27 |
Family
ID=46924422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014115476/04A RU2014115476A (en) | 2011-09-20 | 2012-09-20 | PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS |
Country Status (9)
Country | Link |
---|---|
US (1) | US20140323504A1 (en) |
EP (1) | EP2760863A1 (en) |
JP (1) | JP2014531449A (en) |
KR (1) | KR20140063700A (en) |
CN (1) | CN103874699A (en) |
AU (1) | AU2012311504B2 (en) |
CA (1) | CA2849340A1 (en) |
RU (1) | RU2014115476A (en) |
WO (1) | WO2013041605A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2575710T3 (en) * | 2011-09-22 | 2016-06-30 | Pfizer Inc | Pyrrolopyrimidine and purine derivatives |
WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
SG11201501815UA (en) | 2012-09-10 | 2015-05-28 | Principia Biopharma Inc | Pyrazolopyrimidine compounds as kinase inhibitors |
RU2712220C2 (en) * | 2013-07-31 | 2020-01-27 | Мерк Патент Гмбх | Pyridines, pyrimidines and pyrazines as bruton's tyrosine kinase inhibitors and use thereof |
WO2015038417A1 (en) * | 2013-09-10 | 2015-03-19 | Asana Biosciences, Llc | Compounds for regulating fak and/or src pathways |
US10092569B2 (en) | 2014-02-21 | 2018-10-09 | Principia Biopharma Inc. | Salts and solid form of a BTK inhibitor |
EA036269B1 (en) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Treatment of pemphigus |
WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN106831779B (en) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | The noval chemical compound of a kind of jak kinase inhibitor |
CN115054586B (en) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | Modified release formulations |
EP3484876A1 (en) | 2016-07-14 | 2019-05-22 | Pfizer Inc | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
JOP20180094A1 (en) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | Heterocyclic compound as a protein kinase inhibito |
CN110885331B (en) * | 2018-09-11 | 2021-07-09 | 中国药科大学 | Preparation and application of 6-amino-1H-pyrazolo [3, 4-d ] pyrimidine JAK kinase inhibitor |
US11136329B2 (en) * | 2019-05-08 | 2021-10-05 | Vimalan Biosciences, Inc. | JAK inhibitors |
TW202110849A (en) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna-dependent protein kinase inhibitor |
EP4065578A1 (en) | 2019-11-26 | 2022-10-05 | Theravance Biopharma R&D IP, LLC | Fused pyrimidine pyridinone compounds as jak inhibitors |
WO2021147953A1 (en) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | Pyrimido five-membered ring derivative and application thereof |
CN117412971A (en) * | 2021-05-12 | 2024-01-16 | 微境生物医药科技(上海)有限公司 | Pyrrolopyrimidine derivatives containing pyrazine structures |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0961780T3 (en) | 1997-02-12 | 2007-08-27 | Electrophoretics Ltd | Protein markers for lung cancer and its use |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
KR100838617B1 (en) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | Quinazoline derivatives as angiogenesis inhibitors |
PL203782B1 (en) | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
MXPA02005675A (en) | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | PYRROLO[2,3 d]PYRIMIDINE COMPOUNDS. |
US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
CA2553785C (en) * | 2004-02-14 | 2011-02-08 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0427604D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
PL1891446T3 (en) | 2005-06-14 | 2013-08-30 | Cellzome Gmbh | Process for the identification of novel enzyme interacting compounds |
GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
DK1862802T3 (en) | 2006-06-01 | 2009-04-14 | Cellzome Ag | Method for Identifying ZAP-70 Interacting Molecules and for Purifying ZAP-70 |
KR20090031787A (en) | 2006-07-21 | 2009-03-27 | 노파르티스 아게 | 2,4-di(arylamino)-pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
KR20100014271A (en) | 2006-11-16 | 2010-02-10 | 파마코페이아, 엘엘씨. | 7-substituted purine derivatives for immunosuppression |
US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
JP2010532756A (en) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Combination anti-cancer therapy comprising inhibitors of both mTORC1 and mTORC2 |
AU2009211338B2 (en) * | 2008-02-06 | 2011-12-15 | Novartis Ag | Pyrrolo[2, 3-D] pyrimidines and use thereof as tyrosine kinase inhibitors |
CL2009001884A1 (en) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye. |
GB0903759D0 (en) | 2009-03-04 | 2009-04-15 | Medical Res Council | Compound |
WO2010118986A1 (en) | 2009-04-14 | 2010-10-21 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
JP5918693B2 (en) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | EGFR inhibitor and disease treatment method |
EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
TW201125867A (en) * | 2009-10-20 | 2011-08-01 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
WO2012022681A2 (en) | 2010-08-20 | 2012-02-23 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
-
2012
- 2012-09-20 RU RU2014115476/04A patent/RU2014115476A/en not_active Application Discontinuation
- 2012-09-20 CA CA2849340A patent/CA2849340A1/en not_active Abandoned
- 2012-09-20 US US14/345,512 patent/US20140323504A1/en not_active Abandoned
- 2012-09-20 CN CN201280049382.6A patent/CN103874699A/en active Pending
- 2012-09-20 AU AU2012311504A patent/AU2012311504B2/en not_active Expired - Fee Related
- 2012-09-20 JP JP2014531222A patent/JP2014531449A/en active Pending
- 2012-09-20 KR KR1020147006956A patent/KR20140063700A/en not_active Application Discontinuation
- 2012-09-20 WO PCT/EP2012/068504 patent/WO2013041605A1/en active Application Filing
- 2012-09-20 EP EP12762577.0A patent/EP2760863A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP2760863A1 (en) | 2014-08-06 |
CN103874699A (en) | 2014-06-18 |
WO2013041605A1 (en) | 2013-03-28 |
AU2012311504A1 (en) | 2014-04-10 |
JP2014531449A (en) | 2014-11-27 |
AU2012311504B2 (en) | 2016-03-24 |
CA2849340A1 (en) | 2013-03-28 |
US20140323504A1 (en) | 2014-10-30 |
KR20140063700A (en) | 2014-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014115476A (en) | PYRAZOLO [4, 3-C] PTRIDINE DERIVATIVES AS KINASE INHIBITORS | |
JP2014531449A5 (en) | ||
PE20230161A1 (en) | INHIBITORS OF MUTANT KRAS PROTEINS | |
JP6935415B2 (en) | 2-Amino-N- [7-Methoxy-2,3-dihydroimidazole- [1,2-c] quinazoline-5-yl] pyrimidine-5-carboxamides | |
RU2014141579A (en) | Heterocyclic compounds as beta-lactamase inhibitors | |
RU2011151835A (en) | Pyrazolopyrimidines and Related Heterocycles as Kinase Inhibitors | |
JP2015509975A5 (en) | ||
JP2013529196A5 (en) | ||
RU2015148189A (en) | 2-AMIDOPYRIDO DERIVATIVES [4, 3-d] PYRIMIDIN-5-OH AND THEIR APPLICATION AS WEE-1 INHIBITORS | |
SI3106463T1 (en) | Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors | |
RU2014152790A (en) | Pyrrolopyrazone Inhibitors of Tankyrase | |
JP2004527560A5 (en) | ||
RU2016134751A (en) | COMPOUNDS | |
JP2013523614A5 (en) | ||
JP2013544893A5 (en) | ||
RU2014105624A (en) | COMPOUNDS OF INDAZOL, METHOD OF THEIR APPLICATION AND PHARMACEUTICAL COMPOSITION | |
RU2014126750A (en) | BRUTON TYROSINKINASE INHIBITORS | |
SI2989100T1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
CL2013003647A1 (en) | Compounds derived from pyrrolo [2,3-d] pyrimidine or pyrrolo [2,3-b] pyridine, inhibitors of jak activity; pharmaceutical composition; Useful for the treatment of autoimmune, inflammatory and bone resorption diseases, cancer, myeloproliferative disorders or organ transplant rejection. | |
JP2015514056A5 (en) | ||
RU2015106787A (en) | SUBSTITUTED PYRROLES ACTIVE AS KINASE INHIBITORS | |
AR069510A1 (en) | ARILO AND HETEROARILO IMIDAZO [1,5-A] FUSIONED PIRAZINS AS INHIBITORS OF PHOSPHODIESTERASE 10 | |
JP2014505735A5 (en) | ||
JP2015503507A5 (en) | ||
NZ598907A (en) | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170110 |